2017 ACVIM Forum Research Abstract Program

Dogs (n = 46) with naturally occurring diseases for which PEG was administered for bowel cleansing prior to colonoscopy were prospectively enrolled. Dogs were randomly assigned to be administered maropitant or metoclopramide subcutaneously 30 minutes prior to orogastric tube administration of 66 ml/kg of PEG by or under supervision of the blinded authors. The PEG dose was repeated 2 hours later, but the anti-emetic was not. The incidences of vomiting or regurgitation were 25.8% and 44.9%, respectively. Regurgitation occurred more often in dogs with lower body weight (15.5 kg vs. 24.3 kg, P = 0.021), in dogs with more rapid administration of PEG (Dose 1: 73.7 seconds vs. 112 seconds, P = 0.005; dose 2: 71.6 seconds vs. 111.8 seconds, P = 0.015.), and in female dogs (13/21 vs. 7/25, P = 0.021). When author 2 inserted the orogastric tube, vomiting occurred less often than when Author 1 did so (5/34 vs. 5/9, P = 0.008). There was no difference in incidence of vomiting (Dose 1: 16.7% vs. 23.8%, P = 0.713; Dose 2: 12.5% vs. 21.1%, P = 0.681) or regurgitation (Dose 1: 25.0% vs. 52.4%, P = 0.059; Dose 2: 12.5% vs. 31.6%, P = 0.153) in dogs that received maropitant or metoclopramide, respectively.